LL-37 — Host defense / antimicrobial peptide — sole human cathelicidin; innate immunity effector peptide

LL-37 is the C-terminal 37-amino acid peptide cleaved from the precursor protein hCAP18 (human cathelicidin antimicrobial protein 18) by proteinase 3 in neutrophils and kallikrein 5 in skin. It is the only cathelicidin in the human genome. Mechanisms: (1) Direct membrane disruption of gram-positive and gram-negative bacteria, fungi, and some enveloped viruses by forming amphipathic alpha-helical structures that insert into and disrupt lipid bilayers; (2) Chemotaxis — recruits neutrophils, monocytes, and mast cells to infection sites via formyl peptide receptor-like 1 (FPRL-1) binding; (3) Wound healing — activates keratinocyte migration and proliferation via EGFR transactivation; (4) Immunomodulation — suppresses LPS-induced TLR4 signaling, reducing excessive inflammation; (5) Angiogenesis — promotes VEGF-A expression and endothelial tube formation. Vitamin D3 is the primary regulator of LL-37 gene (CAMP gene) expression — critically important clinical context.

نظرة عامة

هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.

فئة المركّب

Host defense / antimicrobial peptide — sole human cathelicidin; innate immunity effector peptide

آلية العمل

LL-37 is the C-terminal 37-amino acid peptide cleaved from the precursor protein hCAP18 (human cathelicidin antimicrobial protein 18) by proteinase 3 in neutrophils and kallikrein 5 in skin. It is the only cathelicidin in the human genome. Mechanisms: (1) Direct membrane disruption of gram-positive and gram-negative bacteria, fungi, and some enveloped viruses by forming amphipathic alpha-helical structures that insert into and disrupt lipid bilayers; (2) Chemotaxis — recruits neutrophils, monocytes, and mast cells to infection sites via formyl peptide receptor-like 1 (FPRL-1) binding; (3) Wound healing — activates keratinocyte migration and proliferation via EGFR transactivation; (4) Immunomodulation — suppresses LPS-induced TLR4 signaling, reducing excessive inflammation; (5) Angiogenesis — promotes VEGF-A expression and endothelial tube formation. Vitamin D3 is the primary regulator of LL-37 gene (CAMP gene) expression — critically important clinical context.

الوضع التنظيمي

NOT FDA approved. Investigational New Drug (IND) status for topical wound healing. Phase 2 trials completed; Phase 3 not initiated as of 2024.

مستوى الأدلة

B (for chronic wound healing) — Phase 2 RCT by Grönberg et al. (2014, n=34 chronic venous leg ulcers) showed statistically significant wound size reduction vs placebo. No Phase 3 data yet. Investigational product.